Bliztin Drug Interactions

Interaction with food: Food significantly reduces the oral bioavailability of Bilastine by 30%.
Interaction with grapefruit juice: Concomitant intake of Bilastine 20 mg and grapefruit juice decreased Bilastine bioavailability by 30%. This effect may also apply to other fruit juices. The degree of bioavailability decrease may vary between producers and fruits. The mechanism for this interaction is an inhibition of OATP1A2, an uptake transporter for which Bilastine is a substrate. Medicinal products that are substrates or inhibitors of OATP1A2, such as ritonavir or rifampicin, may likewise have the potential to decrease plasma concentrations of Bilastine.
Interaction with ketoconazole or erythromycin: Concomitant intake of Bilastine and ketoconazole or erythromycin increased Bilastine AUC and C_max. These changes can be explained by interaction with intestinal efflux transporter, since Bilastine is substrate for P-gp and not metabolized. These changes do not appear to affect the safety profile of Bilastine and ketoconazole or erythromycin, respectively. Other medicinal products that are substrates or inhibitors of P-gp, such as cyclosporine, may likewise have the potential to increase plasma concentrations of Bilastine.
Interaction with diltiazem: Concomitant intake of Bilastine 20 mg and diltiazem 60 mg increased C_max of Bilastine. This effect can be explained by interaction by intestinal efflux transporters, and does not appear to affect the safety profile of Bilastine.
Interaction with alcohol: The psychomotor performance after concomitant intake of alcohol and 20 mg Bilastine was similar to that observed after intake of alcohol and placebo.
Interaction with lorazepam: Concomitant intake of Bilastine 20 mg and lorazepam 3 mg for 8 days did not potentiate the depressant CNS effects of lorazepam.